Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
Category: #health  By Pankaj Singh  Date: 2019-08-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
  • Outputs from single ascending dose specify that TERN-201 is well tolerated and generally safe & can inhibit plasma SSAO activity.
     
  • This trial has now transitioned onto the next level; multiple-ascending dose phase.

Terns Pharmaceuticals, Inc., an international biopharmaceutical company aimed at developing and discovering innovative therapies to treat cancer and non-alcoholic steatohepatitis (NASH), reportedly announced interim outputs of, currently under progress, clinical trial of TERN-201, an inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), being made for NASH treatment.

Interim data of first clinical study of TERN-201 tells that single, oral TERN-201 administrations were well handled with no important safety findings or any adverse events experienced that would lead to discontinuation. Every dose level studied showed reduction from baseline in SSAO activity of plasma that was maintained up to a week after the single dose TERN-201 administration. Study has now transitioned to multiple dose phase based on these outputs.

Chief Medical Officer of Terns, Erin Quirk, M.D. stated that the data seen till date from the clinical study in Phase 1 of TERN-201 has been encouraging and showed that TERN-201 is capable of being a therapy to treat liver fibrosis and NASH. Terns has further advanced two compounds into clinical development this year with TERN-101, a FXR agonist, and Tern-201 in current studies.

Quirk added that the company looks forward to check further outcomes from Phase 1 studies of TERN-201 and TERN-101 in this year as the company progresses towards its goal of unveiling effective and safe combination treatments for NASH.

Initially, TERN-201 was developed and discovered by Eli Lilly & Company. Terns made a global exclusive deal with Eli Lilly last year to manufacture, develop and commercialize TERN-201 for treating NASH. In Vienna, at International Liver CongressTM 2019, Terns presented preclinical information expressing that TERN-201 enhances NAFLD Activity Score (NAS) & fibrosis in rodent subjects of NASH.

 

Credit Source:

https://www.ternspharma.com/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Chingari secures $15 million funding to strengthen the technological space
Chingari secures $15 million funding to strengthen the technological space
By Pankaj Singh

Chingari, a video-sharing mobile application, has reportedly raised $15 million in a recent funding round headed by Republic Capital. JPIN Venture Catalysts, Onmobile, and Hill Harbour also participated in the funding round along with the angel inve...

Ashok Leyland & Aidrivers sign MoU to develop autonomous vehicles
Ashok Leyland & Aidrivers sign MoU to develop autonomous vehicles
By Pankaj Singh

Under this deal, Aidrivers will offer AI-enabled autonomous solutions while Ashok Leyland will offer vehicle platforms Ashok Leyland, an Indian multinational automotive manufacturer, has reportedly entered into a partnership with Aidrivers, an auton...

T-Mobile debuts rideshare advertising with Octopus Interactive acquisition
T-Mobile debuts rideshare advertising with Octopus Interactive acquisition
By Pankaj Singh

T-Mobile US, a US-based wireless network operator, partly owned by German telecommunications company Deutsche Telekom, has announced successful acquisition of Octopus Interactive, a major network of rideshare screens throughout the United States. Ac...